Trials / Completed
CompletedNCT05021562
A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice
Zedula Special Drug Use Observational Study "Ovarian Cancer"
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 354 (actual)
- Sponsor
- Takeda · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The main aim of this study is to check for side effects from treatment with niraparib. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. During the study, participants with ovarian cancer will take capsules of niraparib (Zedula) once a day according to their clinic's standard practice. The study doctors will check for side effects from niraparib for 1 year after treatment starts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Niraparib | Niraparib capsules |
Timeline
- Start date
- 2021-09-13
- Primary completion
- 2026-03-31
- Completion
- 2026-03-31
- First posted
- 2021-08-25
- Last updated
- 2026-04-13
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05021562. Inclusion in this directory is not an endorsement.